Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin

被引:68
作者
Beall, HD
Liu, YF
Siegel, D
Bolton, EM
Gibson, NW
Ross, D
机构
[1] UNIV COLORADO,HLTH SCI CTR,SCH PHARM,DENVER,CO 80262
[2] UNIV COLORADO,HLTH SCI CTR,CTR CANC,DENVER,CO 80262
[3] UNIV SO CALIF,SCH PHARM,LOS ANGELES,CA 90033
[4] UNIV SO CALIF,CTR CANC,LOS ANGELES,CA 90033
关键词
DT-diaphorase; streptonigrin; cytotoxicity; genotoxicity; bioreductive activation; DNA strand breaks;
D O I
10.1016/S0006-2952(95)00223-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The metabolism, cytotoxicity, and genotoxicity of streptonigrin (SN) were determined in two human colon carcinoma cell lines: HT-29 with high NAD(P)H:quinone oxidoreductase (EC 1.6.99.2, DTD) activity and BE with undetectable DTD activity. Dicumarol-sensitive oxidation of NADH was observed with HT-29 cytosol, but not with BE cytosol. Oxygen consumption was also observed using HT-29 cytosol, but was absent with BE cytosol. Dicumarol inhibited oxygen consumption with HT-29 cytosol, but deferoxamine had no effect, suggesting that divalent metal cations were not necessary for efficient auto oxidation of SN hydroquinone. In cytotoxicity studies, SN was much more toxic to the DTD rich HT-29 cells than to the DTD-deficient BE cells. Deferoxamine decreased toxicity in both cell lines, implicating hydroxyl radicals produced during Fenton-type reactions as the toxic species. In the genotoxicity assay, SN induced a much higher incidence of DNA strand breaks in HT-29 cells than in BE cells, and deferoxamine protected against DNA strand breaks in both cell lines. Some evidence of DNA repair was also observed in the two cell lines. These results support an important role for DTD in the cytotoxicity and genotoxicity of SN in the high DTD HT-29 colon carcinoma cell line.
引用
收藏
页码:645 / 652
页数:8
相关论文
共 45 条
[1]   NADPH CYTOCHROME-P-450 REDUCTASE ACTIVATION OF QUINONE ANTI-CANCER AGENTS TO FREE-RADICALS [J].
BACHUR, NR ;
GORDON, SL ;
GEE, MV ;
KON, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (02) :954-957
[2]  
BANZET P, 1978, CANCER, V41, P1240, DOI 10.1002/1097-0142(197804)41:4<1240::AID-CNCR2820410404>3.0.CO
[3]  
2-J
[4]  
BEALL HD, 1994, CANCER RES, V54, P3196
[5]  
BEALL HD, 1995, MOL PHARMACOL, V48, P499
[6]   USE OF QUINONES IN BRAIN-TUMOR THERAPY - PRELIMINARY-RESULTS OF PRECLINICAL LABORATORY INVESTIGATIONS [J].
BERGER, MS ;
TALCOTT, RE ;
ROSENBLUM, ML ;
SILVA, M ;
ALIOSMAN, F ;
SMITH, MT .
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, 1985, 16 (05) :713-719
[7]   EFFECTS OF STREPTONIGRIN ON CULTURED HUMAN LEUKOCYTES [J].
COHEN, MM ;
CRAIG, AP ;
SHAW, MW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1963, 50 (01) :16-&
[8]   MECHANISM OF DEGRADATION OF DNA BY STREPTONIGRIN [J].
CONE, R ;
HASAN, SK ;
LOWN, JW ;
MORGAN, AR .
CANADIAN JOURNAL OF BIOCHEMISTRY, 1976, 54 (03) :219-223
[9]   HIGH-LEVELS OF EXPRESSION OF THE NAD(P)H-QUINONE OXIDOREDUCTASE (NQO1) GENE IN TUMOR-CELLS COMPARED TO NORMAL-CELLS OF THE SAME ORIGIN [J].
CRESTEIL, T ;
JAISWAL, AK .
BIOCHEMICAL PHARMACOLOGY, 1991, 42 (05) :1021-1027
[10]  
Ernster L, 1967, METHODS ENZYMOL, V10, P309, DOI [10.1016/0076-6879(67)10059-1, DOI 10.1016/0076-6879(67)10059-1]